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Abstract
We used fluorescence in situ hybridization (FISH) assays to identify t(14;18) translocations in
archival paraffin-embedded tumor sections from non-Hodgkin lymphoma (NHL) cases enrolled in
a population-based study. t(14;18) was identified in 54% of 152 cases, including 39% of diffuse large
cell lymphomas (26 of 66 cases) and 84% of follicular lymphomas (36 of 43 cases). Eighty-seven
percent of t(14;18)-positive cases and 57% of t(14;18)-negative cases expressed bcl-2. FISH assays
detected twice as many t(14;18)-positive follicular lymphomas as PCR assays. Overall, study
findings support the use of FISH assays to detect t(14;18) in archival tumor samples for epidemiologic
studies of NHL subtypes.
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1. Introduction
Classification of lymphomas according to common somatic mutations has been suggested to
reduce the etiologic heterogeneity of lymphoma outcomes for epidemiologic research[1–3].
Many lymphoma-associated chromosomal translocations juxtapose the immunoglobulin
heavy chain (IGH) promoter on chromosome 14 with an oncogene whose subsequent
overexpression contributes to lymphomagenesis [1,4]. For example, (14;18) translocations join
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the IGH promoter with the BCL2 gene at 18q21, resulting in constitutive expression of the anti-
apoptotic bcl-2 protein.
A previous study used polymerase chain reaction (PCR) assays to detect t(14;18) in archival
tumor samples from a subset of participants in the Factors Affecting Rural Men (FARM) study
[5,6]. The population-based case-control study reported subtype-specific associations with
various pesticides and other exposures, thus supporting the use of NHL subtypes based on t
(14;18) translocations as outcomes in etiologic research.
We used FISH to identify t(14;18) translocations in the FARM study samples, and we also
evaluated bcl-2 protein expression based on immunohistochemistry. In this report, we describe
the frequency of t(14;18) translocations and bcl-2 expression (overall and according to NHL
subtype) in archival paraffin-embedded lymphoma samples from the population-based FARM
study, compare PCR and FISH assay results for t(14;18), and discuss the utility of FISH-based
molecular subtyping for epidemiologic research.
2. Materials and methods
2.1. Study population
The FARM study, a population-based study of incident, pathologically confirmed
hemolymphatic cancer cases including NHL in Iowa and Minnesota men, was conducted to
evaluate associations with agricultural, other occupational, lifestyle, and medical factors. The
study population and methods were previously described in detail [7,8]. Briefly, cases
diagnosed between 1980 and 1983 among white men aged 30 or older were identified through
hospital and pathology laboratory records (in Minnesota) and the State Health Registry of Iowa.
The study was restricted to white men from areas other than metropolitan Minnesota in order
to increase the proportion with agricultural exposures, the primary focus of the study.
Eighty-nine percent (694) of 780 ascertained NHL cases were enrolled, and the diagnosis of
NHL was confirmed for 622 cases by a pathology review panel [7–9]. NHL cases were limited
to solid tumors; therefore lymphocytic leukemias were not included in the NHL case subgroup.
Controls were 1,245 white males aged 30 or older without a history of hemolymphatic cancer
that were frequency-matched to cases by age (within five-year groups), state, and vital status.
Between 1981 and 1984, detailed information on agricultural exposures, other occupational
exposures, medical history, smoking, and other potential risk factors for NHL were obtained
through in-person structured interviews of cases and controls, or the next-of-kin of deceased
cases and controls [7,10–12].
2.2. t(14;18)-PCR study
In 1997, archival paraffin-embedded tumor blocks were requested and successfully retrieved
for 248 FARM study NHL cases (40% of all NHL cases in the original study) [5,6]. Over half
of the tumor blocks that were not retrieved had been destroyed or lost; the remainder were held
at institutions that declined to participate in the t(14;18)-NHL study. Up to sixteen 5-micron
sections and sixteen 10-micron sections were cut from each archival block. A single pathologist
(GAD) reviewed the first, middle, and last sections to confirm the presence of tumor tissue and
assign NHL subtypes according to the Revised European American Lymphoma classification
scheme (REAL) [13]. Five-micron sections and slides were processed with diethyl
procarbonate (DEPC) to prevent DNAse or RNAse from interfering with future assays [14].
t(14;18)-PCR assays were performed on DNA extracted from 10-micron sections cut from
archival tumor blocks [5,6]. Each reaction used a consensus primer corresponding to the J
segment of the IGH gene on chromosome 14 (5′-ACCTGAGGAGACGGTGAGC-3′) and a
second primer corresponding to the BCL2 major breakpoint region (MBR) on chromosome 18
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(MBR1: 5′-GAGAGTTGCTTTACGTG-GCCTG-3′). Negative samples were subjected to a
second PCR reaction with the IGH consensus primer and a second BCL2 primer 360 base pairs
upstream of the MBR primer (MBR2: 5′-CGCTTGACTCCTTTACGTGCTG-3′). Amplified
DNA was isolated, denatured, and separated by gel electrophoresis, and transferred to a nylon
membrane using a Southern blot procedure. Amplification was confirmed using radiolabeled
probes that hybridized to DNA adjacent to each BCL2 primer site. A 175-base pair segment
of the human hemoglobin beta (HBB) gene was amplified as an internal positive control to
confirm that the DNA extracted from each sample was adequate for PCR amplification of t
(14;18). Fifty-seven samples that were HBB-negative were classified as inadequate for PCR.
Amplification products from 20 of the 68 t(14;18)-positive samples were sequenced to confirm
that unique translocation breakpoints were amplified from each sample.
2.3. t(14;18)-FISH study
For the current study, commercially available FISH IGH and t(14;18) assays were run on 5-
micron sections archived from FARM study tumor blocks (Vysis/Abbot Molecular, Des
Plaines, IL). All sections were stored at 4°C prior to use. NHL subtypes were updated according
to a modified version of the WHO classification scheme based on morphology only [15]. Cases
that would be classified as chronic lymphocytic leukemias/small lymphocytic lymphomas
(CLL/SLL) according to the WHO scheme are referred to as small lymphocytic lymphomas
(SLL) since study cases were limited to solid tumors only. The majority of cases classified as
diffuse large cell lymphomas (DLCL) were probably diffuse large B cell lymphomas
(DLBCL); however, B-cell status was not confirmed. Cases classified as Burkitt lymphomas
(BL) include both Burkitt and Burkitt-like lymphomas.
Assays were run according to the manufacturer’s instructions (Abbot Molecular/Vysis, Des
Plaines, IL) with minor modifications (as described below). Translocations involving IGH on
chromosome 14 were identified using the LSI® IGH Dual Color, Break Apart Rearrangement
Probe which includes a 900 kilobase pair (kb) SpectrumGreen-labeled probe that hybridizes
to the entire IGH variable (V) region, and a 250 kb SpectrumOrange-labeled probe that
hybridizes to the 3′ flanking region (Fig. 1A) (Abbot Molecular/Vysis, Des Plaines, IL). In a
translocation-negative cell, the expected signal pattern is two orange/green (yellow) fusion
signals (Fig. 2A). In translocation-positive cells, separation of one pair of probes produces one
orange and one green signal in addition to the fusion signal associated with the normal copy
of IGH (Fig. 2B). t(14;18) translocations were identified using the LSI® IGH/BCL2 Dual Color,
Dual Fusion Translocation Probe which includes a 1.5 mega base pair SpectrumGreen probe
that spans the entire IGH locus plus 300 kb centromerically, and a 750 kb SpectrumOrange
probe that covers BCL2 plus 250 kb beyond each end of the gene (Fig. 1C). The expected signal
pattern in a normal nucleus is two orange and two green signals (Fig. 2C). In translocation-
positive cells, juxtaposition of an orange and green probe produces one fusion signal in addition
to the separate orange and green signals associated with the normal copies of IGH and BCL2
(Fig. 2D).
We assayed all cases with at least two 5-micron sections available (n = 230) for any IGH
translocation (IGH-FISH). To increase efficiency t(14;18)-FISH assays were performed only
on samples that were of adequate quality to successfully classify them as positive or negative
based on the IGH assay (n=166). Deparaffinization and pretreatment of archival 5-micron
sections was performed using the Vysis® VP2000™ Processor (Abbott Molecular/Vysis, Des
Plaines, IL). Next, a probe mixture containing a 7:1:2 ratio of buffer, fluorescent probe, and
distilled water was applied to each slide. After a coverslip was placed over the tissue and sealed
with rubber cement, the slide was placed in a HYBrite™ machine (Abbott Molecular/Vysis,
Des Plaines, IL) where denaturation occurred at 75°C for 6 minutes, followed by hybridization
at 37°C for 16 to 18 hours.
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A rapid wash procedure was performed to remove unbound probe. Rubber cement was removed
and slides were soaked for 60 minutes at ambient temperature in a 70 ml of solution of sodium
chloride, sodium citrate and non-ionic detergent (2× SSC 0.1 NP40, pH 7–7.5). Next, coverslips
were removed and slides were soaked for 2 minutes in 70 ml of 2× SSC 0.1 NP40 heated to
73°C. After slides were air-dried in darkness, 10μl of DAPI II counterstain was applied and a
new coverslip was placed over the target area. Newly assayed slides were stored at −20°C until
scoring.
2.4. FISH Scoring
FISH assayed sections were scored at room temperature using the 40× and 100× oil objectives
on a Zeiss Axioskope 2 (Carl Zeiss, Thornwood, NY) equipped with a triple bandpass filter
set (DAPI/Green/Orange V.2, Abbott Molecular/Vysis, Des Plaines, IL). Image capture was
done using a color digital Axiocam 412–312 (Carl Zeiss, Thornwood, NY), and the software
Openlab version 4.0.3 (Improvision, Inc, Lexington, MA).
Criteria for scoring were established before performing FISH assays. In other FISH studies,
the cutoff commonly used is 5% (5 cells with translocation out of 100 cells) [16–21]. However,
the samples in this study had fewer readable cells, thus the cutoff was more conservative. Cases
were classified as translocation-positive if more than 30% of cells showed abnormal signal
patterns. For each sample, a minimum of 25 non-overlapping lymphocytes with complete FISH
signals were scored; samples with fewer than 25 readable cells were not classified. A complete
FISH signal was defined as one that included the full set of orange, green or fusion signals
expected in a positive or negative cell; therefore we did not score lymphocytes with truncated
nuclei and incomplete signals, or overlapping cells with signals that could not be differentiated.
In addition, the strength of both the orange and green FISH signals had to be adequate to
distinguish separate signals from fusion signals. The appearance and quality of FISH signals
varied depending on the source of the tissue, the adequacy and type of sample fixation, and the
overall quality of the tissue section. Samples in which the quality of the sample or the strength
of the FISH signals were inadequate to reliably identify positive cells (i.e. samples that did not
include at least 25 cells that could be scored) were classified as unreadable for the assay. Cases
that were unreadable for the IGH assay (n=64) were automatically classified as unreadable for
t(14;18).
Cells other than lymphocytes, for example, epithelial or connective tissue cells in biopsies from
extranodal sites, were not scored. Clonal evolution may result in both positive and negative
neoplastic clones within a single tumor, and the distribution and clustering of neoplastic and
non-neoplastic lymphocytes may vary depending on the tumor site and NHL subtype;
therefore, each section was examined in its entirety for positive lymphocytes before being
classified as translocation-negative. Non-neoplastic lymphocytes, which were present in all
samples, served as internal negative controls.
t(14;18) assays were scored by two investigators (CC and JS). Concordance between the
independent scores was 72% (121/169), including 9 cases that were classified as unreadable
by both scorers. Discordant cases included sections that were classified as unreadable by only
one scorer (26 cases). Discordant cases were subsequently reviewed and assigned a consensus
score when possible, resulting in 152 successfully classified cases.
2.5. bcl-2 expression
bcl-2 immunostaining was performed on paraffin sections from 229 FARM study cases using
a mouse monoclonal antibody (clone 124; Dako) corresponding to bcl-2 amino acids 41–54
(Dako Denmark A/S, Copenhagen, Denmark.). Cases were classified as bcl-2 positive if more
than 20% of cells showed cytoplasmic staining. Twenty-one samples that were inadequate for
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scoring were classified as missing for bcl-2 expression. Scoring was performed by two
investigators (WYH and JS). Independent scores were concordant for 92% of the cases assayed
(191/208).
2.6. Data analysis
FISH data were entered into an Access database (Microsoft Corp., Redmond, WA). Univariate
analyses were performed based on data from 227 cases with complete FISH, PCR, and
immunostaining data using SAS® version 9.1. [22] The distribution of cases according to t
(14;18) and bcl-2 expression was determined by WHO subtype, and t(14;18)-FISH assay
results were compared with results of previous t(14;18)-PCR assays run on the same samples.
3. Results
3.1. Distribution of translocations detected by FISH
t(14;18)-FISH assays were successful on 152 out of 227 cases with complete FISH, bcl-2 and
PCR data, including 82 (54%) that were t(14;18)-positive. Eighty-four percent of follicular
lymphomas (FL) (36 of 43 FL cases successfully assayed) were t(14;18)-positive (Table 1). In
comparison, only 44% of the FL cases successfully assayed by PCR were t(14;18)-positive
(data not shown).
3.2. bcl-2 expression
Over 75% of cases assayed for bcl-2 expression by immunostaining (157 of 206 readable cases)
were bcl-2 positive, including 55 of 59 FL and 29 of 29 SLL (Table 2). bcl-2 expression was
more likely to be positive in t(14;18)-positive cases (87% bcl-2 positive, 67 cases) than t
(14;18)-negative cases (57% positive, 39 cases).
3.3. t(14;18)-FISH versus t(14;18)-PCR
PCR and FISH assays for t(14;18) were concordant for 70% (92/132) of cases successfully
evaluated by both assays, including 39 that were t(14;18)-positive and 53 that were t(14;18)-
negative (Table 3). Among the discordant cases, 32 were PCR-negative/FISH-positive (18 FL,
4 DLCL, 94% bcl-2 positive), and 7 cases were PCR-positive/FISH-negative (1 FL, 3 DLCL,
86% bcl-2 positive). Overall, cases were more likely to be classified as t(14;18)-positive based
on FISH (82 of 152 cases, 54%) than PCR (60 of 170 cases, 35%). The success rate (proportion
of cases with interpretable results) of PCR assays (170 of 227 cases, 75%) was slightly higher
than that of FISH assays (152 of 227 cases, 67%), but almost half of the samples that were
inadequate for FISH (37 of 75) were also inadequate for PCR.
4. Discussion
In general, FISH assay results were consistent with expectations based on previous studies,
with t(14;18) identified in 84% of follicular lymphomas (FL) and 39% of diffuse large cell
lymphomas (DLCL). Other FISH-based studies of FL in the United States (US), Canada,
Europe, China and Malaysia have reported comparable proportions of t(14;18) positive cases
(74–100%); however, Japanese studies have reported lower prevalences (56–64%) (Table 4a).
US studies have also reported similar prevalences of t(14;18) among DLCL (20–32%), but
results for study populations from other countries have varied widely (15–94%) (Table 4b).
Some of the variation in t(14;18) lymphomas may reflect biological differences among
populations [23], but differences in case selection and assay protocols may also contribute to
variation among studies. Variation in the prevalence of t(14;18) DLCL also may reflect
differences in diagnostic criteria among pathologists, who have been shown to be much less
likely to agree on DLCL versus FL diagnoses [24].
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bcl-2 was expressed by the majority of cases in our population, but was more prevalent for t
(14;18) positive (87%) than t(14;18) negative (57%) cases, consistent with expectations. In t
(14;18) negative lymphomas bcl-2 expression may be increased by BCL2 amplification or
hypomethylation, in response to EBV or CMV viral proteins, or through other mechanisms
[25,26].
Overall, our results suggest that FISH was more sensitive than PCR for detecting t(14;18)-
positive tumors, consistent with previous studies [16–19,27,28]. We expected that up to 25%
of true t(14;18)-positive cases would have been false-negative based on PCR [29], which
cannot detect translocation breakpoints that occur outside of the regions bounded by PCR
primers. In addition, PCR may be less specific than FISH because of its potential to detect rare
non-neoplastic t(14;18)-positive lymphocytes that may be present in biopsy samples [30]. This
may explain discordant results for some or all the 7 study cases that were FISH-negative but
PCR-positive for t(14;18). Sample contamination could also have caused false-positive PCR
assays, but precautions were taken to prevent contamination, and sequencing confirmed unique
t(14;18) breakpoints in a subset of samples [5].
Although we cannot confirm the sensitivity and specificity of FISH and PCR relative to a “gold
standard” cytogenetic assay, we believe that the weight of the evidence supports FISH over
PCR as the method of choice for detecting t(14;18) in archival samples for observational
epidemiologic research. FISH also has advantages over karyotyping for observational research
because it does not require fresh tissue, and can be performed on readily available archival
samples, including paraffin-embedded sections over 25 years old, as in our study. In addition,
running in situ FISH assays directly on tumor sections facilitates localization to neoplastic cells
[29].
Disadvantages of FISH assays of preserved samples include the inability to score overlapping
or truncated cells, which contributed to missing outcome data for approximately one-third of
the cases assayed in our study. The cost of commercial FISH probes and the labor and training
required to perform and score assays is also a concern, though costs and labor may be reduced
through the use of tissue microarrays (TMAs) [31–33] and automated scoring [21].
In summary, the frequency of common translocations identified using FISH assays in a
population-based sample of lymphoma cases was generally consistent with expectations. FISH
appeared to be more sensitive to detect t(14;18)-positive tumors than PCR, though we were
unable to formally evaluate either assay against a cytogenetic “gold standard.” Large-scale
epidemiologic studies of lymphoma subtypes should consider the advantages of FISH over
other assays and incorporate strategies for minimizing time and resources (e.g., by running
assays on TMA sections). Large numbers of cases are needed to provide sufficient power to
assess risk factors for translocation subtypes in population-based samples of lymphoma cases.
However, the use of FISH assays to classify lymphomas according to t(14;18) may provide a
relatively simple and efficient means of discovering risk factors and etiologic mechanisms for
a common subset of lymphomas.
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Gene regions corresponding to FISH probes used to detect chromosomal translocations. (A)
IGH gene regions corresponding to LSI IGH Dual Color Break Apart probes used to detect
IGH translocations (regardless of the partner gene). (B) Regions of IGH (upper) and BCL2
(lower) corresponding to LSI IGH/BCL2 Dual Color Dual Fusion probes to detect t(14;18).
Arrows indicate the location of primers used in previous polymerase chain reaction (PCR)
assays, including the Jh consensus primer on chromosome 14, the MBR1 primer for the
BCL2 major breakpoint region (MBR) on chromosome 18, and the MBR2 primer 360 base
pairs upstream of MBR1 (adapted from Abbot Molecular/Vysis, Des Plaines, IL).
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Photomicrographs showing signal patterns expected for FISH assays of normal cells and
translocation positive cells. (A) Vysis LSI IGH Dual Color, Break Apart probe signal pattern
expected for a translocation-negative cell (2 fusion signals) and (B) an IGH-positive cell (1
orange, 1 green, and 1 fusion signal). (C) Vysis LSI IGH/BCL2 Dual Color, Dual Fusion probe
signal pattern expected for a t(14;18)-negative cell (2 orange, 2 green) and (D) a t(14;18)-
positive cell (1 orange, 1 green, and 2 fusion signals).
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Table 1
t(14;18)-positive lymphomas according to histologic subtype based on FISH assays of archival paraffin-
embedded tumor samplesa.
NHL Subtype t(14;18)-positive t(14;18)-negative
N % N %
Follicular 36 84 7 16
Diffuse Large Cell 26 39 40 61
Small lymphocytic 5 33 10 67
Burkitt/Burkitt-like 6 50 6 50
Mantle Cell 3 100 0 0
Marginal zone 0 0 1 100
Lymphoblastic 0 0 1 100
Lymphoplasmacytic 0 0 1 100
Unclassified 6 60 4 40
Total 82 54 70 46
a
NHL subtypes were determined using a modified (World Health Organization) WHO classification scheme based on morphology only. Translocation
status was determined using commercially available FISH assays for t(14;18) (Vysis, Abbott Molecular Inc., Des Plaines, IL).
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Table 2
bcl-2 positive lymphomas according to histologic subtype based on IHC assays of archival paraffin-embedded
tumor samples
NHL Subtype bcl-2-positive bcl-2-negative
N % N %
Follicular 55 93 4 7
Diffuse Large Cell 43 56 34 44
Small lymphocytic 29 100 0 0
Burkitt/Burkitt-like 7 50 7 50
Mantle Cell 4 100 0 0
Marginal zone 2 100 0 0
Lymphoblastic 0 0 1 100
Lymphoplasmacytic 1 100 0 0
Unclassified 16 84 3 16
Total 157 76 49 24
NHL subtypes were determined using a modified (World Health Organization) WHO classification scheme based on morphology only. bcl-2
expression was determined using a mouse monoclonal antibody (clone 124; Dako Denmark A/S, Copehagen, Denmark) corresponding to bcl-2 amino
acids 41–54 run on paraffin-embedded tumor sections. 21 cases were not successfully assayed for bcl-2 expression.
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Table 3
t(14;18)-positive and t(14 ;18)-negative cases based on FISH versus t(14;18)-PCR assays run on archival paraffin-
embedded lymphoma samples
t(14;18)-FISH t(14;18)-PCR
Positive Negative Unreadableb Total
Positive 40 32 10 82
Negative 7 53 10 70
Unreadablea 13 25 37 75
Total 60 110 57 227
t(14;18) status was determined using Vysis LSI IGH/BCL2 Dual Color, Dual Fusion FISH assays. PCR assays used a Jh consensus primer, an MBR1
primer corresponding to the BCL2 major breakpoint region (MBR), and a second primer 360 base pairs upstream of MBR1. Assays were run on
archival paraffin-embedded tumor sections.
a
Unreadable FISH assays could not be scored because of inadequate sample or FISH signal strength.
b
Unreadable PCR assays were negative for the human hemoglobin beta (HBB) internal control and t(14;18).
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